- Conditions
- Acute Lymphobkastic Leukemia, Medication Adherence
- Interventions
- Educational Website, #AYAOSM
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 15 Years to 25 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Philadelphia, Pennsylvania • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 752
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
- Interventions
- Vemurafenib
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Oakland, California • San Diego, California + 15 more
- Conditions
- Liver Cancer (Primary and Metastatic), Renal Cancer
- Interventions
- Not listed
- Lead sponsor
- Palo Alto Veterans Institute for Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Healthy, no Evidence of Disease
- Interventions
- IMPACT intervention, Online education materials, survey administration
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 1,262 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Breast Cancer
- Interventions
- GEH121224 (18F) Injection, Dynamic and Static - PET/CT Scan, Static - PET/CT Scan
- Drug · Diagnostic Test
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Clomipramine
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 2
- States / cities
- Stanford, California • Cincinnati, Ohio
- Conditions
- Pain
- Interventions
- SMART app wearable
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 8 Years to 80 Years
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Leukemia
- Interventions
- topotecan hydrochloride
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 20 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 22 more
- Conditions
- Cardiac Toxicity, Lymphoma
- Interventions
- bleomycin sulfate, filgrastim, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
- Biological · Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2008
- U.S. locations
- 36
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 28 more
- Conditions
- Acute Myeloid Leukaemia
- Interventions
- S 64315 (also referred as MIK665) and azacitidine
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Genetic Predisposition
- Interventions
- Digital Care Plans
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Enterobacterial Infections, Oncologic Disease, Inflammatory Disease, Invasive Fungal Infections
- Interventions
- 18F-FDS PET/CT
- Combination Product
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Bone Metastases, Musculoskeletal Cancer, Soft Tissue Sarcoma, Thromboembolism
- Interventions
- acetylsalicylic acid, enoxaparin, PCD
- Drug · Device
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Metastatic Melanoma
- Interventions
- Bempegaldesleukin (NKTR-214), Nivolumab, ⁸⁹Zr-Df-IAB22M2C
- Biological · Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Duarte, California • Portland, Oregon • Philadelphia, Pennsylvania
- Conditions
- Leukemia, Acute Lymphoblastic
- Interventions
- Acute Lymphobastic Leukemia (ALL) Treatment Options
- Other
- Lead sponsor
- New Mexico Cancer Research Alliance
- Other
- Eligibility
- Not listed
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Breast Cancer, Prehabilitation, Physical Activity, Surgery
- Interventions
- Exercise, Prehabilitation Education
- Behavioral
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Multiple Chronic Conditions
- Interventions
- Patient-reported outcome measure, Comprehensive Medication Review, Pharmacist communication
- Other
- Lead sponsor
- University of Tennessee
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Pharmacokinetic sampling - AZD9291, Simvastatin, AZD9291 tablet dosing, Pharmacokinetic sampling - simvastatin, Pharmacokinetic sampling - AZ5140 and AZ7550
- Procedure · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Carcinoma, Hepatocellular, Cirrhosis
- Interventions
- Abbreviated Magnetic Resonance Imaging with serum AFP, Abdominal Ultrasound Screening with serum AFP
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4,700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 31 more
- Conditions
- Cancer
- Interventions
- SQ3370
- Drug
- Lead sponsor
- Shasqi, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 7
- States / cities
- Duarte, California • Palo Alto, California • Santa Monica, California + 4 more
- Conditions
- Primary Malignant Brain Tumors
- Interventions
- CAU+ (Enhanced Care as Usual), Beating the Blues, SmartCare
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Refractory Metastatic Colorectal Cancer, pMMR, MSS
- Interventions
- RP2, RP3, atezolizumab, bevacizumab
- Biological
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Seattle, Washington
- Conditions
- Advanced Malignancy, Advanced Solid Tumors, Cancer, Oncology, Oncology Patients, Tumors, Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Transitional Cell Carinoma of Bladder, Colorectal Cancer
- Interventions
- AMG 228
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- La Jolla, California • New Haven, Connecticut • New York, New York
- Conditions
- Localized Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
- Interventions
- Interview, Nutritional Therapy, Physical Therapy, Psychosocial Care, Questionnaire Administration
- Other · Procedure · Behavioral
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio